Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...

Clinical trials continue to shape metastatic breast cancer treatment, making therapies safer, more tolerable, and more ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a ...

ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics” (Reference # CTL-21), highlighted the following: Overview of the COMBAT-ALS Clinical Trial: Purpose, ...

The study will conclude when the final patient reaches six months post-chemotherapy. While the exact study completion date is not yet determined, we anticipate that top-line data may be available ...

Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in ...

Innovative approaches to making clinical studies more efficient and cost-effective were a central theme of the 2nd Annual COG ...

AIwithCare features a software platform that uses generative AI to screen patients for clinical trial eligibility.

A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic ...

Mass General Brigham is announcing the spinout of AIwithCare, a company founded by researchers from the health system who developed an artificial intelligence (AI) screening tool that significantly ...